is accepted to be a common pathophysiological factor in the development of pre-eclampsia (de Luca Brunori et al., 1988; Andrea R.Genazzani 1 Rodgers et al., 1988; Roberts et al., 1989; Rappaport et al., 1 Department of Reproductive Medicine and Child Development, 1990; Nisell, 1992; Burrows et al., 1994; Dekker et al., 1995; Division of Gynaecology and Obstetrics, 2 Stella Maris Foundation Dekker and Sibai, 1998). The placenta acts as an immunological barrier between the mother and the fetal 'graft', allowing two antigenically different 4 To whom correspondence should be addressed at: Lung'Arno organisms to tolerate one another. During the course of Simonelli 3, 56100-Pisa, Italy. E-mail: g.arcidiacono@obgyn.med.unipi.it pregnancy this barrier becomes extremely thin, Ͻ2 µm at term, which is only slightly greater than the pulmonary alveolar It is generally accepted that maternal recognition of paternblood/air barrier (Jones and Fox, 1991). It is clear that any ally derived fetal antigens occurs during normal pregnancy damage to this barrier from various ischaemic risk factors and may be beneficial for implantation and maintenance (metabolic, hormonal, genetic, immunological) may be of gestation. Thus, we have investigated the human leukoresponsible for lesions of the syncytiotrophoblast and villous cyte class II DR antigens (HLA-DR), whose role in self and vessel endothelial cells (Jones and Fox, 1980). Therefore, non-self recognition is well known, in women with premixing of maternal and fetal blood is possible, with triggering eclampsia, their partners and in control couples. The of a maternal rejection reaction (de Luca Brunori et al., 1994).
pregnancy this barrier becomes extremely thin, Ͻ2 µm at term, which is only slightly greater than the pulmonary alveolar It is generally accepted that maternal recognition of paternblood/air barrier (Jones and Fox, 1991) . It is clear that any ally derived fetal antigens occurs during normal pregnancy damage to this barrier from various ischaemic risk factors and may be beneficial for implantation and maintenance (metabolic, hormonal, genetic, immunological) may be of gestation. Thus, we have investigated the human leukoresponsible for lesions of the syncytiotrophoblast and villous cyte class II DR antigens (HLA-DR), whose role in self and vessel endothelial cells (Jones and Fox, 1980) . Therefore, non-self recognition is well known, in women with premixing of maternal and fetal blood is possible, with triggering eclampsia, their partners and in control couples. The of a maternal rejection reaction (de Luca Brunori et al., 1994) .
HLA-DR antigens were tested in 70 pre-eclamptic primi-
The concept that pre-eclampsia may be caused by an gravidae women and their partners and 70 healthy control abnormal maternal immune response to antigenic challenge by couples using the serological Terasaki technique. Our the fetal allograft has been analysed by many authors (Jenkins results did not show any particular HLA-DR antigen to be et al., 1977; Stirrat, 1987; El-Roeiy and Gleicher, 1988 ; Sibai, correlated with pre-eclampsia, but a statistically significant 1991; Redman, 1992; Vinatier and Monnier, 1995) . Following increase of only one identifiable HLA-DR antigen, which this immunological hypothesis, we previously undertook an was presumed to express homozygosity at the HLA-DR immunohistochemical study, using HLA-DR monoclonal antilocus, in the pre-eclamptic women and their partners: 67.1 body in placentae from pre-eclamptic women. We observed versus 7.9% in the control couples (P < 0.000001). The intense and widespread expression of the HLA-DR antigens, analysis of HLA-DR compatibility between pre-eclamptic absolutely absent in the control placentae (de Luca Brunori women and their partners showed a statistically highly et al., 1994) . This reaction is similar to that which precedes significant increase of the female-to-male compatibility the hyperacute rejection reaction in transplanted human kidney (P ⍧ 0.0003) and a lower but significant male-to-female and heart (Gille, 1980; Caforio et al., 1990) . compatibility in comparison with controls (P ⍧ 0.014).
To understand the mechanism at the basis of such an evident From our results, it emerges that HLA-DR homozygosity immunological reaction in pre-eclampsia, we undertook the and reduced antigenic disparity seem to be associated to a present study to evaluate if pre-eclampsia, like transplant major risk for pre-eclampsia, which consequently appears rejection, could be related to the immunological role of the to be a 'couple's disease'.
Introduction
their partners and 70 control couples were examined using the Pre-eclampsia is a severe gestational pathology that represents Terasaki serological HLA-DR typing technique. All pre-eclamptic an impending danger both for the mother and her fetus. The women were selected according to the criteria of the Davey and aetiology of this pathology is still undefined, although it is MacGillivray classification of hypertensive disorders in pregnancy: generally accepted that implantation, which is an outstanding systolic blood pressure ജ140 mm Hg, diastolic blood pressure example of successive interactions between two genetically ജ90 mm Hg on two occasions at least 6 h apart; proteinuria ജ300 distinct tissues (Edwards, 1995a,b) , is impaired in pre-eclampmg/24 h (Davey and McGillivray, 1988) . All blood pressure levels were measured at hospital admission of patients and 6 h later for the sia. In fact, abnormal trophoblastic invasion occurs in early diagnosis of pre-eclampsia and then measured daily by hourly Table II . Neonatal outcome in pre-eclamptic women monitoring using Symphony N-3100-100 (Nellcor Puritan Bennett, Pleasanton, CA, USA); proteinuria was quantified in all pre-eclamptic Time of delivery n (%) Neonatal weight Survival women by taking urine samples in the first 24 h after admission.
(completed weeks) (g, mean Ϯ SD)
The group of pre-eclamptic women included 69 Italian Caucasian
Alive Dead couples and one South-American couple. All women were singleton
primigravidae, between the 26th and 35th week of gestation, aged 29 years on average; they had no history of hypertension, diabetes, healthy babies. This control group was made up of Italian Caucasian couples from the same geographical area as the couples in the study group to avoid any difference in ethnic composition between groups.
Aliquots of 9 ml of venous blood samples were taken in 1 ml significant excess of only one HLA-DR antigen in the partners adenine-citrate-dextrosium (ACD) solution tubes, and examined using of the couples of pre-eclamptic women versus controls (67.1 the standard lymphocytotoxicity technique for HLA-DR typing versus 7.9%; P Ͻ 0.000001) (Tables III and IV) . As we used (Terasaki and McLelland, 1964) . Each couple included in the study a wide range of typing sera, we presumed that, for the majority and the control group was typed by means of two 72-well plates of the cases, the presence of a single detected HLA-DR antigen (Terasaki plates ; One Lambda Inc., Canoga Park, CA, USA) differing indicated homozygosity at this locus.
in sera composition in order to use a very wide serological range. female and heterozygous male), III (heterozygous female and
In order to make the DR typing data uniform, the results were homozygous male) and only two couples belonged to group reported as broad antigen specificities from 1 to 10.
IV (both heterozygous partners). In the majority of the controls,
The HLA-DR typing results of the pre-eclamptic and control groups both partners carried two DR antigens (group IV) and only 10 were compared using the χ 2 test. All differences were considered to couples were distributed in groups I, II and III.
be statistically significant when P Ͻ 0.05. The relative risk (RR)
The distribution of HLA-DR homozygosity in the study was calculated by Woolf's method (Woolf, 1955 ) with Haldane's group (Table IV) was either in both partners, 26/70 cases modification (Haldane, 1956 ).
(37.1%), or only in women, 22/70 cases (31.4%), or only in men, 20/70 cases (28.6%). No significant difference in Results homozygosity frequency was found between the partners in the couples of pre-eclamptic women. The clinical details of the pre-eclamptic women, regarding the time and kind of delivery, proteinuria, blood pressure and Out of the two couples of pre-eclamptic heterozygous partners, the first was HLA-DR identical (female DR 6,7; male maternal endangering are reported in Table I . The neonatal outcome is described in Table II , in which the time of delivery DR 6,7) while the second shared one DR specificity (female DR 2,5; male DR 4,5). reflects the severity of pre-eclampsia and explains the perinatal mortality (38.5% in the babies delivered at or before the 26th
Pre-eclampsia was extremely severe for perinatal mortality and/or maternal endangering (eclampsia, pleural and pericardial week; 0% in the babies delivered at or later than the 35th week).
The HLA-DR typing did not show any particular antigen effusion) in 24/26 couples in whom both partners were homozygous and also in the above mentioned couple of clearly associated with pre-eclampsia, but the occurrence of a Table III . HLA-DR in couples of pre-eclamptic women and control couples 1,5 1 7,9 2,4 1 4,6 1,9 1
Group I: both homozygous partners. Group II: homozygous female and heterozygous male. Group III: homozygous male and heterozygous female. Group IV: both heterozygous partners. F ϭ female; M ϭ male; n ϭ number of couples with the same DR pattern.
heterozygous but DR identical partners (female DR 6,7; male associated with pre-eclamptic pregnancies generally possess a smaller total number of different HLA-DR specificities than DR 6,7).
We have also analysed the antigenical variety (i.e. the control couples. The HLA-DR sharing between partners of the study and number of different DR antigens in the couple) and the antigenical disparity (i.e. the DR specificities not shared by control groups did not show any significant difference (21 versus 25 couples, not significant; Table III ). the partners) (Table V) . From this table, it emerges that parents The analysis of the HLA-DR compatibility between partners, increase of male-to-female compatibility (RR 4.6, P ϭ 0.014) in comparison with controls (Table III) . female to male (i.e. when the DR of the female is compatible with that of the male) and male to female (i.e. when the DR In the 20 couples of pre-eclamptic women and 10 control couples checked by PCR in addition to the Terasaki method, of the male is compatible with that of the female), showed a statistically significant increase in the female-to-male compatthe results of the biological molecular technique confirmed the serological data (Tables VI, VII) . ibility (RR 30.13, P ϭ 0.0003) and a lower but significant
